Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marta Gil-Martin, Patricia Gomez Pardo, Sara Lopez-Tarruella, Luis Manso, Jose Alejandro Perez-Fidalgo, Foluso Olabisi Ademuyiwa, Ingrid A. Mayer, Timothy J. Pluard, Maria Martinez Garcia, Peter A. Kaufman, Linda T. Vahdat, Leon W. Hooftman, Barbara Romagnoli, Cristina Hernando, Katherine N. Weilbaecher, Eva M. Ciruelos, Miguel Martin, Sonia Pernas Simon, Javier Cortes
Institutions: Institut Català d'Oncologia, Vall d'Hebron Institute of Oncology, Hospital General Universitario Gregorio Marañón, Hospital Universitario 12 De Octubre, Hospital Clínico Universitario de Valencia, Washington University in St. Louis, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Saint Luke's Hospital, Hospital Del Mar, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Weill Cornell Medicine, Polyphor (Switzerland)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2693783263